Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 25, 2023

Q-TWiST Analysis of Survival Benefits With Brigatinib vs Crizotinib in Patients With ALK-Positive NSCLC

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial
Lung Cancer 2023 Nov 01;185(2023)107376, MR Garcia Campelo, Y Wan, HM Lin, T Chen, J Shen, P Zhang, DR Camidge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading